Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2026
    • The 2026 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Educational Assets
    • Manufacturer Search
    • Podcasts
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Views
    • Video
  • 2026 Leadership
    • 2025 Winners
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • Subscribe

Launch of Novel Agents for the Treatment of Hepatitis C Virus Will Precipitate Treatment of At Least Half of ‘Warehoused’ Patients

September 27, 2010 By Bio-Medicine.Org

BURLINGTON, Mass., Sept. 27 /PRNewswire/ — Decision Resources,
one of the world’s leading research and advisory firms for
pharmaceutical and healthcare issues, finds that the launch of
novel therapies for the treatment of Hepatitis C Virus (HCV),
including Vertex/Johnson & Johnson/Mitsubishi Tanabe’s
telaprevir and Merck’s boceprevir, will precipitate several changes
in HCV treatment. According to Patient Flow in Hepatitis C
Virus
, surveyed physicians plan to initiate treatment in at
least half of their “warehoused” HCV1 patients one year after novel
therapies become available. Patient “warehousing” is a term that
has been coined to characterize the phenomenon of HCV patients
opting out of treatment with current standard of care in
anticipation of new therapies; psychiatric events, adverse events
and liver health are top reasons keeping patients away from current
therapies.

The report also finds that time from initial diagnosis to
treatment initiation will decrease once novel HCV therapies are
available. On average, surveyed physicians stated they wait 17
months to initiate treatment in HCV1 treatment-naive patients; this
time will decrease to 7 months once novel treatment options are
available.

“The arrival of telaprevir and boceprevir will alter more than
the drug-treatment rate and treatment initiation timing in HCV,”
said Alexandra Makarova, M.D., Ph.D. “Physicians indicate they
would increase the capacity of their HCV practice to accommodate
the additional patients expected once novel therapies are
available.”

About Patient Flow in Hepatitis C VirusPatient Flow in
Hepatitis C Virus
is a 15-year, annualized patient forecast for
each of the G7 countries that estimates the total size of the
declining prevalent HCV population and segments it by viremic
status, HCV genotype and line of therapy. It includes two
components: an Excel workbook containing quantitative analysis,
including patient forecast and modifiable assu

‘/>”/>

SOURCE

Related Articles Read More >

An illustration showing the Autus size-adjustable heart valve being expanded years after implantation with a minimally invasive balloon catheter.
The first-of-its-kind Autus pediatric heart valve is designed for expansion and durability
The MIT researcher's implant, LUCID.
MIT researchers design implantable ultrasound-powered drug delivery device to minimize tumor recurrence
An image of the Teleflex Freesolve RMS resorbable magnesium scaffold.
Teleflex Interventional leader sees resorbables as ‘the next frontier’ of PCI
Feminai's breast sensor patch
AdvaMed and MedTech Innovator name 2026 prize winners and finalists
“mdo
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest medical device business news, application and technology trends.

DeviceTalks Weekly

See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

New MedTech Resource

Medical Tubing

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to our E-Newsletter
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2026 Arrowfly, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2026
    • The 2026 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Educational Assets
    • Manufacturer Search
    • Podcasts
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Views
    • Video
  • 2026 Leadership
    • 2025 Winners
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • Subscribe